These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 18663817)

  • 41. CYP2D6 genotype in relation to hot flashes as tamoxifen side effect in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial.
    Dezentjé VO; Gelderblom H; Van Schaik RH; Vletter-Bogaartz JM; Van der Straaten T; Wessels JA; Kranenbarg EM; Berns EM; Seynaeve C; Putter H; Van de Velde CJ; Nortier JW; Guchelaar HJ
    Breast Cancer Res Treat; 2014 Jan; 143(1):171-9. PubMed ID: 24265036
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Don't think twice it's all right: tamoxifen and CYP2D6 genotyping in the treatment of breast cancer patients.
    Damkier P
    Pharmacogenomics; 2017 Jun; 18(8):753-754. PubMed ID: 28592184
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Important and critical scientific aspects in pharmacogenomics analysis: lessons from controversial results of tamoxifen and CYP2D6 studies.
    Kiyotani K; Mushiroda T; Zembutsu H; Nakamura Y
    J Hum Genet; 2013 Jun; 58(6):327-33. PubMed ID: 23657426
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on CYP2D6 and Tamoxifen.
    Goetz MP
    Clin Adv Hematol Oncol; 2013 Mar; 11(3):178-80. PubMed ID: 23598986
    [No Abstract]   [Full Text] [Related]  

  • 45. CYP2D6 polymorphisms as predictors of outcome in breast cancer patients treated with tamoxifen: expanded polymorphism coverage improves risk stratification.
    Schroth W; Hamann U; Fasching PA; Dauser S; Winter S; Eichelbaum M; Schwab M; Brauch H
    Clin Cancer Res; 2010 Sep; 16(17):4468-77. PubMed ID: 20515869
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity.
    Ahern TP; Hertz DL; Damkier P; Ejlertsen B; Hamilton-Dutoit SJ; Rae JM; Regan MM; Thompson AM; Lash TL; Cronin-Fenton DP
    Am J Epidemiol; 2017 Jan; 185(2):75-85. PubMed ID: 27988492
    [TBL] [Abstract][Full Text] [Related]  

  • 47. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
    Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
    Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Understanding resistance to tamoxifen in hormone receptor-positive breast cancer.
    Higgins MJ; Stearns V
    Clin Chem; 2009 Aug; 55(8):1453-5. PubMed ID: 19541862
    [No Abstract]   [Full Text] [Related]  

  • 49. Comment on 'Impact of CYP2D6*10 on recurrence-free survival in breast cancer patients receiving adjuvant tamoxifen therapy'.
    Lash TL; Ahern TP; Cronin-Fenton D; Garne JP; Hamilton-Dutoit S; Sørensen HT
    Cancer Sci; 2008 Aug; 99(8):1706-7. PubMed ID: 18754887
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adjuvant endocrine therapy for premenopausal women with early breast cancer.
    Dellapasqua S; Colleoni M; Gelber RD; Goldhirsch A
    J Clin Oncol; 2005 Mar; 23(8):1736-50. PubMed ID: 15755982
    [No Abstract]   [Full Text] [Related]  

  • 51. Inherited gene affects tamoxifen's benefit in some breast cancers.
    Mayo Clin Womens Healthsource; 2006 Jun; 10(6):3. PubMed ID: 16675918
    [No Abstract]   [Full Text] [Related]  

  • 52.
    Wei X; Cai J; Zhuang J; Zheng B; Sui Y; Zhang G; Lin Y; Sun H
    Pharmacogenomics; 2020 Jan; 21(1):43-53. PubMed ID: 31769341
    [No Abstract]   [Full Text] [Related]  

  • 53. Effect of CYP2C19 and CYP2D6 genotype on tamoxifen treatment outcome indicates endogenous and exogenous interplay.
    Sim S; Lövrot J; Lindh JD; Bergh J; Xie H
    Pharmacogenomics; 2018 Aug; 19(13):1027-1037. PubMed ID: 30022682
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacogenomics toward personalized tamoxifen therapy for breast cancer.
    Zembutsu H
    Pharmacogenomics; 2015; 16(3):287-96. PubMed ID: 25712191
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tamoxifen benefits and CYP2D6 testing in women with hormone receptor-positive breast cancer.
    Kaplan M; Mahon SM
    Clin J Oncol Nurs; 2013 Apr; 17(2):174-9. PubMed ID: 23538253
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of CYP2D6-genotype on tamoxifen efficacy in advanced breast cancer.
    Karle J; Bolbrinker J; Vogl S; Kreutz R; Denkert C; Eucker J; Wischnewsky M; Possinger K; Regierer AC
    Breast Cancer Res Treat; 2013 Jun; 139(2):553-60. PubMed ID: 23686417
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CYP2D6*4 polymorphism: A new marker of response to hormonotherapy in male breast cancer?
    Abreu MH; Gomes M; Menezes F; Afonso N; Abreu PH; Medeiros R; Pereira D; Lopes C
    Breast; 2015 Aug; 24(4):481-6. PubMed ID: 25963137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacogenomics of endocrine therapy in breast cancer.
    Weinshilboum R
    Adv Exp Med Biol; 2008; 630():220-31. PubMed ID: 18637494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. CYP2D6 genotype as a marker for benefit of adjuvant tamoxifen in postmenopausal women: lessons learned.
    Kelly CM; Pritchard KI
    J Natl Cancer Inst; 2012 Mar; 104(6):427-8. PubMed ID: 22395645
    [No Abstract]   [Full Text] [Related]  

  • 60. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
    Pharoah PD; Abraham J; Caldas C
    J Natl Cancer Inst; 2012 Aug; 104(16):1263-4; author reply 1266-8. PubMed ID: 22851268
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.